2023 World Conference on Lung Cancer (Posters)-P2.08. EDGE-Lung: A Phase 2 Open-Label Platform Study to Evaluate Immunotherapy-Based Combinations in Patients with Metastatic NSCLC

P2.08. EDGE-Lung: A Phase 2 Open-Label Platform Study to Evaluate Immunotherapy-Based Combinations in Patients with Metastatic NSCLC - PDF(Slides)

Pdf Summary

Summary Not Available

Asset Subtitle

Melissa Johnson

Meta Tag

Speaker Melissa Johnson

Topic Metastatic NSCLC: Immunotherapy - TIPs